Agenus Inc
NASDAQ:AGEN
Agenus Inc
Revenue
Agenus Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Agenus Inc
NASDAQ:AGEN
|
Revenue
$156.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
34%
|
CAGR 10-Years
48%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Agenus Inc's Revenue?
Revenue
156.3m
USD
Based on the financial report for Dec 31, 2023, Agenus Inc's Revenue amounts to 156.3m USD.
What is Agenus Inc's Revenue growth rate?
Revenue CAGR 10Y
48%
Over the last year, the Revenue growth was 60%. The average annual Revenue growth rates for Agenus Inc have been 21% over the past three years , 34% over the past five years , and 48% over the past ten years .